7:04 AM ET
8-K
Clinical Trial Data
Korro Bio Clinical Trial Data
Korro Bio announced positive preclinical results for KRRO-111, its RNA-editing development candidate for Alpha-1 Antitrypsin Deficiency (AATD). The studies demonstrated up to 95% mRNA editing and a 6-fold increase in total functional AAT protein, supporting a potential best-in-class profile for treating both lung and liver manifestations of the disease.